Clinical Trial Update: Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib in patients with metastatic kidney cancer that did not respond to sunitinib or bevacizumab. Results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-02-01